Animal Health Innovation
Animal Health Innovation
Search
Human Health Partnering
Human Health Partnering
Open Innovation Boehringer Ingelheim
Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines
Skin Diseases
Skin Diseases | We discover and develop breakthrough therapies that can be used to prevent, treat and repair many inflammatory and fibrotic diseases.
Across Cancer Types
Across Cancer Types
Research at Regional Center Vienna
RCV is the regional affiliate of Boehringer Ingelheim and responsible for over 30 countries in Central and Eastern Europe and Central Asia.
Our Responsibility
Human Health Our Responsibility
Retinal Diseases
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
Boehringer Ingelheim Awards Innovation Prize to Ablevia
Innovative solution from Ablevia for rapid and selective elimination of harmful antibodies without impediment to the immune system
Immune cell directed therapies
Boehringer Ingelheim is committed to transforming cancer care, investigating therapies that target cancer cells and boost the immune system for the benefit of patients.
Embracing diversity in clinical trials: A global mandate
Have you ever wondered why medicines work differently for different people? Each patient is unique. By embracing diversity in clinical trials, we enable more equitable and inclusive healthcare.
Venture Fund searching for groundbreaking trends
The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
The global $1 trillion mental health problem needs more funding
Nearly one billion people around the world live with a mental health condition, yet an estimated 70% don’t have access to the help they need.
Partnering
We are convinced that diversity and exchange in science give birth to innovations. For this reason, partnerships are an important component of our innovation strategy.
Boehringer Ingelheim’s Postdoctoral Program
Boehringer Ingelheim’s postdoctoral program in Regional Center Vienna (RCV) provides scientists with the opportunity to pursue research.
Making sustainable medicines through eco-design
Our goal is to minimize the environmental footprint of our medicines through integration of eco-design and green chemistry across the entire lifecycle
Biotherapeutics Discovery
Our committed team of scientists are using all their experience and knowledge to forge new research paths, engineer new molecules and do whatever it takes to make sure that no patient is left behind in our search for the next breakthrough.
Cancer cell directed therapies
At Boehringer Ingelheim, we are investigating cancer cell directed therapies that target key cancer drivers and hallmarks to directly kill cancer cells.
New cancer research building: Boosting innovation in oncology
With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.
Improving the current state of schizophrenia care
A closer look at the status of the schizophrenia care landscape, an often misunderstood mental health condition
Small Molecule Drug Discovery
Boehringer Ingelheim scientists continue to expand the horizons of what small molecule drugs can achieve.